Ambrilia Biopharma

Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the development of novel treatments for viral diseases and cancer. The Company's current strategy is to capitalize on its broad product portfolio through out-licensing and divestment.

Ambrilia's product portfolio includes: a sustained release octreotide formulation for treating acromegaly, a sustained release goserelin formulation for treating prostate cancer and other indications, HIV protease, integrase and entry inhibitors, HCV entry and polymerase inhibitors and Influenza A inhibitors.

The company has elected to prioritize divestment of its oncology assets and has put a hold on antiviral R&D activities. This divestment strategy aims to generate non-dilutive R&D funding for Ambrilia and to preserve the companies cash flow.